title: [Suppressive effect of recombinant immunomodulator ronkoleukin on the blood level of antiinflammatory cytokines, anticardiolipin autoantibodies and heart failure].
abstract: OBJECTIVE
  To elucidate clinical efficacy and immunocorrecting properties of recombinant immunomodulator ronkoleukin in patients with postinfarction cardiac dysfunction with NYHA FC II-III CHF.
  
  
  METHODS
  In a 6-months prospective comparative clinically controlled study we observed 33 survivors of myocardial infarction divided into 2 groups according to FC of chronic heart failure (CHF): group I (n=17) with FC II CHF with LVEF > 45% (mean age 52 +/- 2.9 years) and group II (n=16) with FC III CHF and lowered ( 40%) LVEF (mean age 53.7 +/- 3.3 years). Comparison group comprised practically healthy subjects. Clinico-laboratory and functional assessment of state of patients was carried out before initiation of therapy with ronkoleukin and in 2 - 3 days after completion of 2 courses of therapy with 3 months interval. Immunological study included determination of subpopulation content of peripheral blood lymphocytes, blood plasma immunoglobulins, antiinflammatory cytokines Il-1a, Il-1b, Il-2, Il-6, Il-8, TNFa and AB to Cl.
  
  
  RESULTS
  It was found that ronkoleukin is an effective immunocorrector producing no adverse effects in patients with FC II-III CHF. Most pronounced effect ronkoleukin manifested in relation to humoral immunity lowering dysimmunoglobulinemia, blood levels of IgA, IgG, CIC and antibodies to cardiolipin, inhibiting excessive cytokine activation in dependence on degree of severity of CHF.
  
  
  CONCLUSIONS
  Administration of ronkoleukin to patients with postinfarction dysfunction of the heart with FC II-III CHF for correction of secondary immunodeficient state in addition to basic therapy provides positive changes of hematological, immunological parameters, intracardiac hemodynamics, facilitates regression of symptoms of CHF and improves quality of life.
authors.forename: A T
authors.initials: AT
authors.lastname: Tepliakov
authors.forename: L A
authors.initials: LA
authors.lastname: Bolotskaia
authors.forename: T A
authors.initials: TA
authors.lastname: Stepacheva
authors.forename: N V
authors.initials: NV
authors.lastname: Karaman
authors.forename: E V
authors.initials: EV
authors.lastname: Rybal'chenko
authors.forename: S N
authors.initials: SN
authors.lastname: Shilov
authors.forename: A P
authors.initials: AP
authors.lastname: Maslov
mesh_terms: D017153:Antibodies, Anticardiolipin / Q000097:blood* / Q000187:drug effects*; D001323:Autoantibodies / Q000097:blood / Q000187:drug effects; D016207:Cytokines / Q000097:blood / Q000378:metabolism*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D018487:Ventricular Dysfunction, Left / Q000453:epidemiology
chemical_list: D017153:Antibodies, Anticardiolipin; D001323:Autoantibodies; D016207:Cytokines; D007155:Immunologic Factors